Hormonal
Oral semaglutide administration in patients with type 2 diabetes significantly reduces body weight, HbA1c, and total cholesterol within 3-6 months, with additional systolic blood pressure reduction observed by 6-12 months.
If you have Type 2 Diabetes, oral semaglutide can significantly improve your weight, blood sugar (HbA1c), and cholesterol levels within the first 6 months, with blood pressure improvements continuing up to a year. While gastrointestinal side effects like nausea are common and may lead some to stop the medication, serious safety issues were not observed in this real-world study. It serves as a viable alternative to injectable GLP-1s, particularly for those who prefer oral medication or have needle phobia.
Oral semaglutide associated with significantly reduced bodyweight (− 3.3 kg), body mass index (BMI) (– 0.9 kg/m2), glycated hemoglobin (HbA1c) (− 11 mmol/mol), and total cholesterol (− 0.4 mmol/l) by 3–6 months follow-up. At 6–12 months, there was a significant reduction in systolic blood pressure (− 7.0 mmHg), in addition to sustained reductions in other metabolic parameters.
Why this rating
Real-world observational study with no control group and relatively small sample size (n=76), limiting causal inference compared to RCTs.
Source
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
David M. Williams et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01590-x
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →